Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 patients.

de Laat JM, Pieterman CR, Weijmans M, Hermus AR, Dekkers OM, de Herder WW, van der Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B, Vriens MR, Valk GD.

J Clin Endocrinol Metab. 2013 Oct;98(10):4143-51. doi: 10.1210/jc.2013-1800. Epub 2013 Aug 16.

PMID:
23956349
2.

Standard pre- and postoperative determination of chromogranin a in resectable non-functioning pancreatic neuroendocrine tumors--diagnostic accuracy: NF-pNET and low tumor burden.

Jilesen AP, Busch OR, van Gulik TM, Gouma DJ, Nieveen van Dijkum EJ.

Dig Surg. 2014;31(6):407-14. doi: 10.1159/000370007. Epub 2015 Jan 6. Review.

PMID:
25572908
3.

Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours?

Walter T, Chardon L, Chopin-laly X, Raverot V, Caffin AG, Chayvialle JA, Scoazec JY, Lombard-Bohas C.

Eur J Cancer. 2012 Aug;48(12):1766-73. doi: 10.1016/j.ejca.2011.11.005. Epub 2011 Nov 29.

PMID:
22133573
4.

Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors.

Panzuto F, Severi C, Cannizzaro R, Falconi M, Angeletti S, Pasquali A, Corleto VD, Annibale B, Buonadonna A, Pederzoli P, Delle Fave G.

J Endocrinol Invest. 2004 Jan;27(1):6-11.

PMID:
15053236
5.

Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients.

Qiu W, Christakis I, Silva A, Bassett RL Jr, Cao L, Meng QH, Gardner Grubbs E, Zhao H, Yao JC, Lee JE, Perrier ND.

Clin Endocrinol (Oxf). 2016 Sep;85(3):400-7. doi: 10.1111/cen.13119. Epub 2016 Jun 30.

PMID:
27256431
6.

Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.

Hijioka M, Ito T, Igarashi H, Fujimori N, Lee L, Nakamura T, Jensen RT, Takayanagi R.

Cancer Sci. 2014 Nov;105(11):1464-71. doi: 10.1111/cas.12533. Epub 2014 Oct 18.

7.

Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas.

Qiao XW, Qiu L, Chen YJ, Meng CT, Sun Z, Bai CM, Zhao DC, Zhang TP, Zhao YP, Song YL, Wang YH, Chen J, Lu CM.

BMC Endocr Disord. 2014 Aug 7;14:64. doi: 10.1186/1472-6823-14-64.

8.

The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.

Modlin IM, Kidd M, Bodei L, Drozdov I, Aslanian H.

Am J Gastroenterol. 2015 Aug;110(8):1223-32. doi: 10.1038/ajg.2015.160. Epub 2015 Jun 2.

PMID:
26032155
9.

Preoperative assessment of the pancreas in multiple endocrine neoplasia type 1.

Lewis MA, Thompson GB, Young WF Jr.

World J Surg. 2012 Jun;36(6):1375-81. doi: 10.1007/s00268-012-1539-7.

PMID:
22382771
10.

Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours.

Nikou GC, Marinou K, Thomakos P, Papageorgiou D, Sanzanidis V, Nikolaou P, Kosmidis C, Moulakakis A, Mallas E.

Pancreatology. 2008;8(4-5):510-9. doi: 10.1159/000152000. Epub 2008 Sep 3.

PMID:
18765956
11.

Clinical usefulness of plasma chromogranin a in pancreatic neuroendocrine neoplasm.

Paik WH, Ryu JK, Song BJ, Kim J, Park JK, Kim YT, Yoon YB.

J Korean Med Sci. 2013 May;28(5):750-4. doi: 10.3346/jkms.2013.28.5.750. Epub 2013 May 2.

12.

Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.

Belli SH, Oneto A, Aranda C, O'Connor JM, Domenichini E, Roca E, Méndez G, Bestani MC, Parma P, Giacomi N, Marmissolle F.

Acta Gastroenterol Latinoam. 2009 Sep;39(3):184-9.

PMID:
19845257
13.

Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1.

Thomas-Marques L, Murat A, Delemer B, Penfornis A, Cardot-Bauters C, Baudin E, Niccoli-Sire P, Levoir D, Choplin Hdu B, Chabre O, Jovenin N, Cadiot G; Groupe des Tumeurs Endocrines (GTE).

Am J Gastroenterol. 2006 Feb;101(2):266-73.

PMID:
16454829
14.

Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1.

Peracchi M, Conte D, Gebbia C, Penati C, Pizzinelli S, Arosio M, Corbetta S, Spada A.

Eur J Endocrinol. 2003 Jan;148(1):39-43.

15.

EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1.

van Asselt SJ, Brouwers AH, van Dullemen HM, van der Jagt EJ, Bongaerts AH, Kema IP, Koopmans KP, Valk GD, Timmers HJ, de Herder WW, Feelders RA, Fockens P, Sluiter WJ, de Vries EG, Links TP.

Gastrointest Endosc. 2015 Jan;81(1):159-167.e2. doi: 10.1016/j.gie.2014.09.037.

PMID:
25527055
16.

Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study.

Zatelli MC, Torta M, Leon A, Ambrosio MR, Gion M, Tomassetti P, De Braud F, Delle Fave G, Dogliotti L, degli Uberti EC; Italian CromaNet Working Group.

Endocr Relat Cancer. 2007 Jun;14(2):473-82.

17.

[The diagnostic value of plasma chromogranin A in neuroendocrine tumors].

Yang XO, Li JN, Qian JM, Yang H, Chen Q, Lu L.

Zhonghua Nei Ke Za Zhi. 2011 Feb;50(2):124-7. Chinese.

PMID:
21418832
18.

Plasma chromogranin A in patients with multiple endocrine neoplasia type 1.

Granberg D, Stridsberg M, Seensalu R, Eriksson B, Lundqvist G, Oberg K, Skogseid B.

J Clin Endocrinol Metab. 1999 Aug;84(8):2712-7.

PMID:
10443665
19.

Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.

Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, Cherfi A, Öberg KE.

J Clin Endocrinol Metab. 2011 Dec;96(12):3741-9. doi: 10.1210/jc.2011-0666. Epub 2011 Oct 12.

PMID:
21994954
20.

Limitations of Chromogranin A in clinical practice.

Marotta V, Nuzzo V, Ferrara T, Zuccoli A, Masone M, Nocerino L, Del Prete M, Marciello F, Ramundo V, Lombardi G, Vitale M, Colao A, Faggiano A.

Biomarkers. 2012 Mar;17(2):186-91. doi: 10.3109/1354750X.2012.654511. Epub 2012 Feb 6.

PMID:
22303881
Items per page

Supplemental Content

Write to the Help Desk